. . . These new stringent rules will strongly impact the pipeline of scientific talent the NIH has provided the biopharm industry.
Howard A. Young, Ph.D.
Advertisement
Articles by Howard A. Young, Ph.D.
Advertisement
Latest Updated Articles
- Final Word: NIH-Biopharm Interactions and the New NIH Conflict-of-Interest Regulations
Published: June 1st 2005 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
Why Flexibility and Commercial Viability Must Be Built-in Early for Scaling CGTs
2
Industry Leaders Detail Transformational Strategies to Mainstream CAR-T Care
3
How Rentschler Biopharma’s New Platforms Aim to Accelerate Biologics Development in Asia
4
Analyzing the Safety and Scope of Next-Generation Gene Editing Platforms
5
